Amphastar Pharmaceuticals, Inc.AMPH财报
Nasdaq · 医疗保健 · 药物制剂
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
AMPH 2025财年Q4 Key Financial Metrics
营收
$183.1M
毛利润
$85.7M
营业利润
$35.6M
净利润
$24.4M
毛利率
46.8%
营业利润率
19.4%
净利率
13.3%
同比增长
-1.8%
EPS
$0.51
Amphastar Pharmaceuticals, Inc. 2025财年Q4 财务摘要
Amphastar Pharmaceuticals, Inc. 2025财年Q4营收 $183.1M（同比下降 1.8%），净利润 $24.4M（同比下降 35.7%）（净利率 13.3%）。销售成本 $97.4M，运营费用 $50.1M。
核心财务指标
| 总营收 | $183.1M |
|---|---|
| 净利润 | $24.4M |
| 毛利率 | 46.8% |
| 营业利润率 | 19.4% |
| 报告期 | 2025财年Q4 |
营收拆解
Amphastar Pharmaceuticals, Inc. 2025财年Q4营收 $183.1M 共来自 6 个业务板块，最大板块 Other Products 贡献 $62.4M（占 34.1%）。
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Other Products | $62.4M | 34.1% |
| Baqsimi | $46.7M | 25.5% |
| Primatenemist | $27.9M | 15.3% |
| Epinephrine | $17.1M | 9.3% |
| Lidocaine | $14.9M | 8.1% |
| Glucagon | $14.1M | 7.7% |
Amphastar Pharmaceuticals, Inc. 分部营收 — 季度趋势
Amphastar Pharmaceuticals, Inc. 过去 4 个季度各业务板块营收走势，展示 Other Products和Baqsimi 等业务的变化。
| 业务分部 | 2025财年Q4 | 2025财年Q3 | 2025财年Q2 | 2025财年Q1 |
|---|---|---|---|---|
| Other Products | $62.4M | $64.1M | $53.1M | $50.0M |
| Baqsimi | $46.7M | $53.6M | $46.7M | $38.4M |
| Primatenemist | $27.9M | $28.8M | $22.9M | $29.1M |
| Epinephrine | $17.1M | $18.8M | $16.2M | $18.6M |
| Lidocaine | $14.9M | $12.9M | $15.0M | $13.6M |
Amphastar Pharmaceuticals, Inc. 年度营收
Amphastar Pharmaceuticals, Inc. 历年营收汇总，含各年度总量（例如 2025 年营收为 $719.9M）
Amphastar Pharmaceuticals, Inc. 季度营收与净利润历史
Amphastar Pharmaceuticals, Inc. 最近 8 个季度的营收、净利润及同比增速
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| 2025财年Q4 | $183.1M | -1.8% | $24.4M | 13.3% |
| 2025财年Q3 | $191.8M | +0.3% | $17.4M | 9.0% |
| 2025财年Q2 | $174.4M | -4.4% | $31.0M | 17.8% |
| 2025财年Q1 | $170.5M | -0.8% | $25.3M | 14.8% |
| 2024财年Q4 | $186.5M | +4.7% | $38.0M | 20.4% |
| 2024财年Q3 | $191.2M | +5.9% | $40.4M | 21.1% |
| 2024财年Q2 | $182.4M | +25.2% | $37.9M | 20.8% |
| 2024财年Q1 | $171.8M | +22.7% | $43.2M | 25.1% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $171.8M | $182.4M | $191.2M | $186.5M | $170.5M | $174.4M | $191.8M | $183.1M |
| 同比增长 | 22.7% | 25.2% | 5.9% | 4.7% | -0.8% | -4.4% | 0.3% | -1.8% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $1.57B | $1.49B | $1.55B | $1.58B | $1.63B | $1.62B | $1.67B | $1.63B |
| 总负债 | $902.0M | $778.2M | $817.5M | $845.2M | $875.0M | $857.9M | $889.5M | $840.5M |
| 股东权益 | $672.4M | $713.3M | $727.7M | $732.3M | $751.3M | $757.5M | $776.7M | $788.8M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $55.3M | $69.1M | $60.0M | $29.0M | $35.1M | $35.6M | $52.6M | $32.9M |